8-K: Assembly Biosciences Announces Positive Interim Phase 1a Results for ABI-1179 in Recurrent Genital Herpes

Assembly Biosciences reports positive interim Phase 1a results for ABI-1179, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor, showing it was well-tolerated with a favorable pharmacokinetic profile, supporting once-weekly oral administration.

Summary

• Assembly Biosciences announced positive interim Phase 1a results from its clinical trial evaluating ABI-1179 for recurrent genital herpes.
• ABI-1179, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor, demonstrated a half-life of approximately four days.
• The drug exhibited high exposure across the evaluated dose range, supporting the potential for once-weekly oral administration at a low dose.
• Assembly Bio plans to move ABI-1179 directly into the Phase 1b portion of the ongoing Phase 1a/b study in participants with recurrent genital herpes.
• The Phase 1b study will run concurrently with the ongoing Phase 1b study for ABI-5366, with interim data for both candidates anticipated in fall 2025.
• In the Phase 1a study, ABI-1179 exceeded Assembly Bio's target plasma concentrations for antiviral activity, even at the lowest dose of 50 mg.
• Treatment-emergent adverse events were mild in intensity and not related to study treatment.

Sentiment

Score: 8

Explanation: The document presents positive interim results from a Phase 1a clinical trial, indicating promising potential for ABI-1179. The drug was well-tolerated, and its pharmacokinetic profile supports convenient once-weekly dosing. The management's comments are optimistic, and the company is moving forward with Phase 1b. However, it's still early-stage development, and risks remain.

Positives

• ABI-1179 was well-tolerated with a favorable safety profile.
• The drug has a half-life of approximately four days, supporting once-weekly oral dosing.
• ABI-1179 exceeded target plasma concentrations for antiviral activity at all doses evaluated.
• Assembly Bio is advancing ABI-1179 directly into Phase 1b, indicating confidence in the drug's potential.
• The Phase 1b study will run concurrently with the ABI-5366 study, potentially accelerating the development timeline.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ.
• These risks include Assembly Bio's ability to maintain financial resources, realize the benefits of its collaboration with Gilead, and initiate and complete clinical studies.
• Safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio's product candidates.

Future Outlook

Assembly Bio plans to move ABI-1179 directly into Phase 1b and report interim data for both ABI-1179 and ABI-5366 in fall 2025, which will inform critical next steps in their data-driven portfolio strategy.

Management Comments

• Jason Okazaki, chief executive officer and president of Assembly Bio, stated that no new therapeutic innovation has been made in decades for recurrent genital herpes.
• He also mentioned that both ABI-1179 and ABI-5366 exceeded their target pharmacokinetic profile for their long-acting helicase-primase inhibitor program.

Industry Context

The announcement addresses the unmet need for new treatments for recurrent genital herpes, as no new drugs have been approved in the United States or Europe for more than 25 years. The helicase-primase inhibition mechanism is a clinically validated approach that has shown potential for superior efficacy compared to nucleoside analogs.

Comparison to Industry Standards

• Current standard of care for recurrent genital herpes includes nucleoside analogs like acyclovir, valacyclovir, and famciclovir.
• These treatments are only partially effective in preventing recurrences and reducing transmission.
• Assembly Bio's helicase-primase inhibitors target a different mechanism and aim to provide superior efficacy.
• Gilead Sciences is a major player in antiviral drug development, and their collaboration with Assembly Bio adds credibility to the program.
• Companies like BioCryst Pharmaceuticals and AiCuris are also developing antiviral therapies, but their specific targets and indications may differ.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of ABI-1179 could improve the lives of millions of people living with recurrent genital herpes.
• Employees may benefit from the company's progress and potential growth.
• The collaboration with Gilead Sciences could strengthen the company's position and resources.

Next Steps

• Assembly Bio plans to move ABI-1179 directly into the Phase 1b portion of the ongoing Phase 1a/b study.
• The Phase 1b study will run concurrently with the ongoing Phase 1b study for ABI-5366.
• Assembly Bio plans to report interim data for both candidates together in fall 2025.
• Assembly Bio expects to submit complete data from the trial for presentation at future scientific meetings.

Key Dates